COVID-19 severity prediction in patients with chronic hepatitis C depending on the liver fibrosis stage
https://doi.org/10.20340/vmi-rvz.2024.2.COVID.1
Abstract
The aim of the study was to develop a method for assessing the risk of severity of the novel coronavirus infection COVID-19 in patients with chronic hepatitis C depending on the severity of liver fibrosis.
Object and methods. The results of laboratory data of patients with COVID-19 and chronic hepatitis C (n = 147) were analyzed. According to the severity of liver fibrosis, patients with COVID-19 with chronic hepatitis C were divided into 3 subgroups: mild fibrosis (F1), moderate fibrosis (F2), severe fibrosis (F3). In blood serum, the parameters of total and biochemical (C-reactive protein, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, gamma-globulins, ferritin) blood tests, lipid profile (high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B), hemostasis (fibrinogen, activated partial thromboplastin time), cytokines (interleukin-2, tumor necrosis factor-а). All parameters were assessed in the acute period, depending on the severity of COVID-19 and the stage of liver fibrosis.
Outcomes. Computer program for predicting the severity of COVID-19 in patients with chronic hepatitis C, depending on the stage of liver fibrosis, can be introduced into clinical practice for managing patients in the certain group.
About the Authors
E. N. Temnik
Samara State Medical University
Russian Federation
Russian Federation
Elizaveta I. Temnik, Assistant of the Department of Infectious Diseases with Epidemiology
89, Chapaevskaya str., Samara, 443099
D. Yu. Konstantinov
Samara State Medical University
Russian Federation
Russian Federation
Dmitriy Yu. Konstantinov, Dr. Sci. (Med.), Docent, Head of the Department of Infectious Diseases with Epidemiology
89, Chapaevskaya str., Samara, 443099
L. L. Popova
Samara State Medical University
Russian Federation
Russian Federation
Larisa L. Popova, Dr. Sci. (Med.), Professor, Professor of the Department of Infectious Diseases with Epidemiology
89, Chapaevskaya str., Samara, 443099
N. P. Persteneva
Samara State University of Economics
Natal'ya P. Persteneva, Cand. Sci. (Econ.), Docent, Associate Professor of the Department of Statistics and Econometrics
141, Sovetskaya Armiya str., Samara, 443090
References
1. 1 World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard Global Situation. Geneva: WHO; 2022. Avaible from: https://covid19.who.int/ Accessed [1/15/23]
2. 2 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. https://doi.org/10.1001/jama.2020.2648
3. 3 Russp FP, Burra P, Zanetto A. COVID-19 and liver disease: where are we now? Nat Rev Gastroenterol Hepatol. 2022;19: 277–278. https://doi.org/10.1038/s41575-022-00607-9
4. 4 Bucurica S., Ionita Radu F., Bucurica A., Socol C., Prodan I., Tudor I., Sirbu C.A., Plesa F.C., Jinga M. Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions—Review of the Literature. Medicina. 2023;59:62. https://doi.org/10.3390/medicina59010062
5. 5 Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html Accessed [11/15/22]
6. 6 Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation-2023. Version 18. (In Russ).
7. 7 Clinical recommendations "Chronic viral hepatitis C" Ministry of Health of the Russian Federation. Year of approval: 2021. (In Russ).
8. 8 Certificate of state registration of the computer program No. 2024615615 Russian Federation. Program for predicting the severity of the course of the new coronavirus infection COVID-19 in patients with chronic hepatitis C : No. 2024614478 : application 02/29/2024 : publ. 03/11/2024 / E.I. Temnik, D.Y. Konstantinov, L.L. Popova ; applicant Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation. (In Russ).
Review
For citations:
Temnik E.N., Konstantinov D.Yu., Popova L.L., Persteneva N.P. COVID-19 severity prediction in patients with chronic hepatitis C depending on the liver fibrosis stage. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2024;14(2):6-11. (In Russ.) https://doi.org/10.20340/vmi-rvz.2024.2.COVID.1
Views:
284
Email this article 